A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
Actual Study Start Date: August 24, 2020
Estimated Primary Completion Date: August 30, 2024
Estimated Study Completion Date: December 30, 2027
Arm:
- Experimental: Atezolizumab + Tiragolumab
- Active Comparator: Durvalumab
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 800 |
| Actual Study start date | 24 August 2020 |
| Estimated Study Completion Date | 30 December 2027 |